NCT01086319View on ClinicalTrials.gov

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

CompletedOBSERVATIONAL

Enrollment

113,505

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Diabetes Mellitus, Type 2

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

University of Pennsylvania

OTHER

lead

AstraZeneca

INDUSTRY

NCT01086319 - Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments | Biotech Hunter | Biotech Hunter